URO ONCO

Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Interview at ESMO 2014 with Dr. Jennifer Cullen, Rockville, USA

Prediction of prostate cancer prognosis using a 17-gene panel
Genomic health developed panel was validated in their cohort not to replace PSA but predict biochemical recurrence, metastases and death of prostate cancer. The gene panel will not replace PSA for the early diagnosis but will help predict the risk of progression in the individual patient. The 17-gene panel (oncotype-DX) is used in conjunction with available clinical predictors such as stage and Gleason grade. The 17-gene panel predicted equally well in Caucasian and African-Americans.

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Subscribe

URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.